New Upfront Treatment Algorithm Emerges for Chronic Lymphocytic Leukemia

According to Susan M. O’Brien, MD, an expert in the treatment of chronic lymphocytic leukemia, novel agents and new data on patient subsets...

Breast Cancer

ASCO Adapts CCO Guideline on Selection of Optimal Adjuvant Therapies for HER2-Negative and HER2-Positive Breast Cancers

As reported in the Journal of Clinical Oncology by Neelima Denduluri, MD, and colleagues, ASCO has adapted a Cancer Care Ontario...

Supportive Care
Symptom Management

Scalp Cooling for Chemotherapy-Induced Alopecia Becoming Mainstream

Hair loss can be a devastating side effect of chemotherapy, but the recent U.S. Food and Drug Administration approval of the DigniCap...


More Top Stories


Nathan Fowler, MD, and Sagar Lonial, MD, on Treating Follicular Lymphoma

Hepatobiliary Cancer

Phase III RESORCE Study Data Show Regorafenib Improves Overall Survival in Previously Treated Patients With Unresectable Liver Cancer

Results from the phase III RESORCE trial show that regorafenib (Stivarga) tablets achieved a median overall survival improvement in patients with unresectable hepatocellular carcinoma that progressed after treatment with sorafenib (Nexavar) tablets. The study, presented by Jordi Bruix, MD, et al...


Melanoma MicroRNA Trafficking May Control Tumor Primary Niche Formation

Researchers at Tel Aviv University (TAU) may have unraveled the metastatic mechanism of melanoma. According to a paper published by Dror et al in Nature Cell Biology, scientists discovered that before spreading to other organs, a melanoma tumor sends out tiny vesicles containing molecules of...


Susan M. O’Brien, MD, on ALL/Lymphoma: Upfront and Salvage Treatments in Older Patients

Gynecologic Cancers

FDA Approves First HPV Test for Use With SurePath Preservative Fluid

On July 7, 2016, the U.S. Food and Drug Administration (FDA) approved the Roche cobas HPV Test as the first test for human papillomavirus (HPV) that can be used with cervical cells obtained for a Papanicolau (Pap) test and collected in SurePath Preservative Fluid.

The FDA approves HPV tests to be...


CAR T-Cell Therapy Promising in Non-Hodgkin Lymphoma

Research conducted at the Fred Hutchinson Cancer Research Center, Seattle, is moving the field of chimeric antigen receptor (CAR) T-cell therapy forward in the treatment of B-cell malignancies. At the 2016 Pan Pacific Lymphoma Conference in Koloa, Hawaii, David G. Maloney, MD, PhD, Professor of...

Study Finds More Nodes Should Be Examined to Rule Out Node-Negative Disease in Papillary Thyroid Cancer

The proportion of patients with papillary thyroid cancer identified as having node-negative disease decreased substantially with an increased number of lymph nodes examined, according to an analysis of data from the National Cancer Database. Robinson and colleagues, of Duke University, reported...


David G. Maloney, MD, PhD, on Lymphomas: Treatment With CAR T Cells

Measures of Success

I was raised to be an engineer. I grew up in an industrial community, worked summer jobs in a U.S. Steel chemical plant, and was good at science and math. My career choice was straightforward: I went to an engineering university. My first semester freshman year included a mandatory introduction ...


Influence of Patients’ Side-Effect Expectations on Outcome of Endocrine Treatment for Breast Cancer

A study of women receiving hormone therapies such as tamoxifen as part of their treatment for breast cancer found that the number and seriousness of side effects they experienced were influenced by their expectations. The study, published by Nestoriuc et al in Annals of Oncology, found that women...

click me